Johannes F E Mann

14PUBLICATIONS
58CO-AUTHORS
Nutrigenomics and personalised nutritionBehavioural epidemiologyNephrology and urologyClinical nutritionCharacterisation of biological macromolecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|May 20, 2026
Response to Comment on Mann et al. Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial. Diabetes Care 2026;49:257-265.

|Mar 29, 2026
Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone.

Rajiv Agarwal, Ricardo Correa-Rotter, Sankar D Navaneethan

|Feb 18, 2026
Kidney and Survival Outcomes with Semaglutide by CKD Severity in the FLOW Trial.

Katherine R Tuttle, Johannes F E Mann, Manuel M Mayrdorfer

|Dec 11, 2025
Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial.

Johannes F E Mann, Nikolaus Marx, John E Deanfield

|Nov 06, 2025
Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial.

Amy Mottl, Charlie Scott, Jennifer B Green

|Sep 18, 2025
Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia: Pre-Specified Analysis of CONFIDENCE.

Rajiv Agarwal, Jennifer B Green, Hiddo J L Heerspink

Pageof 3

Frequent Collaborators

6 joint publications

Peter Rossing

4 joint publications

Richard Pratley

3 joint publications

Janet B McGill

3 joint publications

Amy Mottl